Track Pulmonx Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Pulmonx Corporation LUNG · Stock Open Pulmonx Corporation in new tab

2.86 USD
EPS
-0.96
P/B
3.64
ROE
-90.31
Beta
0.17
Target Price
3.70 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-0.96
Book Value0.79
Price to Book3.64
Debt/Equity164.75
% Insiders4.656%
Growth
Revenue Growth0.06%
Estimates
Forward P/E-3.12
Forward EPS-0.92
Target Mean Price3.70

DCF valuation

Model fair value for Pulmonx Corporation (LUNG)
Result
Sign in to run the valuation for LUNG.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus None · mean target 3.70 USD (low 2.50, high 5.00) · as of 15 Nov 2026
Low 2.50
Mean 3.70
High 5.00
Price 2.86
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Pulmonx Corporation Logo Pulmonx Corporation Analysis (LUNG)

United States Health Care Official Website Stock

Is Pulmonx Corporation a good investment? Pulmonx Corporation (LUNG) is currently trading at 2.86 USD. Market analysts have a consensus price target of 3.70 USD. This suggests a potential upside from current levels.

Earnings Schedule: Pulmonx Corporation is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.92.

Investor FAQ

Does Pulmonx Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Pulmonx Corporation?

Pulmonx Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.96.

Company Profile

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Exchange Ticker
NMS (United States) LUNG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion